Ponesimod Regimen Slowing Brain Volume Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective methods to slow brain volume loss in multiple sclerosis patients, as current therapies are not sufficiently efficacious or well-tolerated.
Innovation Solution
Administering ponesimod using a regimen that is effective in slowing brain volume loss, either alone or in combination with other therapeutic agents, to patients with multiple sclerosis, including those with relapsing-remitting or secondary progressive disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat multiple sclerosis, then some level of brain volume loss prevention is achieved, but the efficacy is insufficient and tolerance is poor
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of S1P1 receptor modulators to create ponesimod with optimized pharmacological properties. This includes adjusting molecular parameters to achieve selective S1P1 receptor binding while reducing off-target effects, thereby improving both efficacy in preventing brain volume loss and tolerability profile compared to previous therapies
2Reliability
If brain tissue is lost in multiple sclerosis patients, then neurological impairment and disability worsen, but lost brain tissue cannot be recovered
Solution Approach 1:
The patent applies preliminary action by administering ponesimod before significant brain tissue loss and irreversible neurological damage occur. The treatment aims to prevent brain volume loss and protect remaining brain tissue through early and sustained therapy, leveraging the drug's ability to reduce inflammation and prevent demyelination before irreversible damage sets in
3Reliability
If therapies are designed to prevent brain volume loss, then efficacy may improve, but safety and tolerability must be maintained
Solution Approach 1:
The patent uses the S1P1 receptor as an intermediary target to achieve brain volume loss prevention while maintaining safety. Ponesimod selectively binds to S1P1 receptors on lymphocytes, modulating their egress from lymph nodes and reducing autoimmune inflammation in the central nervous system. This targeted mechanism provides efficacy while the selective action on specific cell types helps maintain an acceptable safety profile
Data Source
AI summary
The disclosure relates to methods of slowing brain volume loss. In certain aspects, methods of slowing brain volume loss in a patient with multiple sclerosis are disclosed.